Trial Evaluating Cardiovascular Outcomes With Sitagliptin
TECOS is managed by the Duke Clinical Research Institute and the University of Oxford Diabetes Trial Unit. The TECOS Executive Committee has responsibility for oversight of the trial with the majority of members being independent academics. The Operations Committee, which facilitates trial oversight at the local level, comprises academic investigators.
Merck & Co. Inc. – Whitehouse Station, NJ USA
A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes after Treatment with Sitagliptin in Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control
Sitagliptin is a once daily orally administered dipeptidyl peptidase-IV inhibitor which is used to improve glycemic control in type 2 diabetes mellitus (T2DM). Sitagliptin inhibits the inactivation of the incretin hormones GLP-1 and GIP, which in turn stimulates insulin secretion and suppresses glucagon secretion in a glucose-appropriate manner.
Patients aged 50 years or older with type 2 diabetes and documented vascular disease in the coronary, cerebral, or peripheral arteries, who have inadequate glycemic control (HbA1c of ≥6.5% and ≤8.0%). Patients need to be on stable doses of either monotherapy or dual combination therapy with metformin, pioglitazone, or a sulfonylurea i.e. no adjustments to oral antihyperglycemic therapy in the previous 3 months. We also allow patients receiving insulin, either alone or in combination with a stable dose of metformin, but medication must be stable for at least 3 months. Patients must have a usual diabetes care provider whom they visit at least twice yearly.
Global pragmatic trial of approximately 14,000 patients conducted in over 600 experienced clinical sites in Australasia, Asia, Europe, North America, South America, India and South Africa. Streamlined data collection and adverse event reporting. Recruiting sites that have a proven track record for recruiting high numbers of patients as well as sustained enrollment over time and retention of patients for the duration of the trial.
Integrated study design with no interruption in usual care. Sitagliptin vs Placebo will be added to the ongoing care regimen.
To compare the impact of adding sitagliptin to usual care vs. usual care without sitagliptin with regard to the risk of developing cardiovascular events.
Streamlined follow up incorporating data collected from usual healthcare practices. Screening/Randomization (performed at same visit), Clinic visits at 4, 8 and 12 months after randomization during the first year, then annual visits interspersed with short office visits every 6 months for approximately 4-5 years. Telephone follow-up will occur commencing at Month 15 and continue every six months thereafter until the completion of the trial.
Trial sites will be paid a fixed per patient fee which will cover study related expenditure including institution overheads and patient related reimbursement. Sites will be paid quarterly based on attended visits and 'clean' data which will be monitored by the Data Co-ordinating Centre.
Priority given to sites with:
Institutional Review Board submissions to begin Quarter 4, 2008
First Patient in December 2008